⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243 | 0.87 | — | — | |
| SCHEMBL245776 | 0.87 | — | — | |
| SCHEMBL12258 | 0.84 | — | — | |
| SCHEMBL5494 | 0.84 | CTSL (0.39) | — | |
| SCHEMBL5251 | 0.84 | CTSL (0.39) | — | |
| SCHEMBL1145727 | 0.80 | — | — | |
| SCHEMBL4574675 | 0.80 | — | — | |
| SCHEMBL1145901 | 0.70 | — | — | |
| SCHEMBL7985484 | 0.70 | — | — | |
| SCHEMBL487051 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370522-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | Nikang Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | claimed |
| CN-117980310-A | Alkylene derivatives as KRAS inhibitors | 尼坎治疗公司 | 2024-05-03 | — | — | CN | claimed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | claimed |
| WO-2023118098-A1 | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | claimed |
| WO-2023118123-A1 | COMBINATION OF AN Α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | claimed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | claimed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | claimed |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | claimed |
| WO-2023284730-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | claimed |
| CN-114929694-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2022-08-19 | — | — | CN | claimed |
| EP-1472255-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-03 | — | — | EP | claimed |
| EP-1263751-B1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2004-06-16 | — | — | EP | claimed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| US-20030232880-A1 | 2-Phenylpyran-4-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2003-12-18 | — | — | US | claimed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | claimed |
| WO-2003064423-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | claimed |
| EP-1263751-A1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | Almirall Prodesfarma AG (CH) | 2002-12-11 | — | — | EP | claimed |
| WO-2001068633-A1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2001-09-20 | — | — | WO | claimed |
| US-5716904-A | FOR BROARD LEAF WEEDS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | claimed |
| EP-0764641-A1 | NOVEL 4,5-DISUBSTITUTED PYRIMIDINE DERIVATIVE AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-26 | — | — | EP | claimed |